Skip to main content
Midas Edge

Ikena Oncology, Inc.

For the period ended Jun 30, 2025. Filed Jul 24, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 24, 2025

IMA$3.81-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalIncomeDeficitEquity
Balance as of December 31, 202448,258,111$48$457,437$68$(331,619)$125,934
Stock-based compensation expense——904——904
Other comprehensive income———31—31
Net loss————(8,619)(8,619)
Balance as of March 31, 202548,258,11148458,34199(340,238)118,250
Stock-based compensation expense——458——458
Other comprehensive loss———(34)—(34)
Net loss————(2,767)(2,767)
Balance as of June 30, 202548,258,111$48$458,799$65$(343,005)$115,907
Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalLossDeficitEquity
Balance as of December 31, 202348,258,111$48$452,142$(48)$(282,385)$169,757
Stock-based compensation expense——2,001——2,001
Other comprehensive loss———(265)—(265)
Net loss————(16,146)(16,146)
Balance as of March 31, 202448,258,11148454,143(313)(298,531)155,347
Stock-based compensation expense——1,279——1,279
Other comprehensive loss———(37)—(37)
Net loss————(13,730)(13,730)
Balance as of June 30, 202448,258,111$48$455,422$(350)$(312,261)$142,859
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.